1. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
- Author
-
Lawrence Blonde, Xuejun Victor Peng, Alka Shaunik, Rory J. McCrimmon, Anders H. Boss, Kyu Rhee, Supriya Kumar, Sidhartha Balodi, Claire Brulle-Wohlhueter, and Luigi F. Meneghini
- Subjects
medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,Basal insulin ,Glycemic ,Real-world evidence ,business.industry ,Medical record ,Brief Report ,medicine.disease ,chemistry ,IBM Explorys database ,Cohort ,Observational study ,Glycated hemoglobin ,business - Abstract
Introduction Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic medical records (EMR) data from the IBM® Explorys database to evaluate the probability of achieving glycemic control over 24 months after BI initiation in patients with T2D in the USA. Methods A cohort of 6597 patients with T2D who started BI following OAD(s) and had at least one valid glycated hemoglobin (HbA1c) result recorded both within 90 days before and 720 days after BI initiation were selected. We estimated the changes from baseline in HbA1c every 6 months, the quarterly conditional probabilities of reaching HbA1c
- Published
- 2018